Showing: 1 - 5 of 5 RESULTS

Sidero Bioscience Announces Agreement with SRS Life Sciences for Commercialization of BioFe for Iron Deficiency

Sidero Bioscience, LLC, (Hershey, PA) a clinical stage biotechnology company targeting human digestive health, today announces the execution of a term sheet agreement with SRS Life Sciences PTE. LTD, (Singapore) a leading life sciences company. The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.

“This agreement illustrates the excellent partners and licensing opportunities available for our robust and intuitive BioFe technology,” noted Darren Wolfe, Ph.D., President & CEO, Sidero, adding “Iron Deficiency remains a massive global unmet medical need, one that BioFe addresses with natural biology instead of chemicals. We are encouraged by the eagerness of the SRS team to work with us and expect a binding agreement in the near term.”

“At SRS Life Sciences, we exist to change what’s possible for the health of the 6 billion people living in emerging nations. We continuously identify the most pressing unmet healthcare needs so we can be first to deliver products and solutions that lessen the burden of disease,” states Suchet Rastogi, CEO, SRS Life Sciences. Mr. Rastogi continues, “With BioFe, our initial target is to move the needle on the 468 million women suffering from anemia.”

Iron Deficiency (ID), the most common and widespread global nutritional disorder, affects over 2 billion people and causes about 1 million deaths/year (predominantly in Africa/Southeast Asia). The WHO estimates a staggering $2 trillion annual global economic cost due to micronutrient deficiencies, with iron being the most common. ID, which frequently progresses to Iron Deficiency Anemia (IDA), is associated with numerous medical conditions and symptoms, affecting all ages – prenatal to elderly. In the young, ID impedes motor and mental development leading to lifelong physical and cognitive deficiencies. In adults, ID causes fatigue, reduced work capacity, and reduced quality of life among many other symptoms. Iron deficiency is also linked to restless leg syndrome (RLS), hearing deficits, and heart failure and kidney disease morbidity. Significantly, even mild Iron Deficiency leads to decreased physical/athletic performance and also decreased intellectual/cognitive performance.

James Connor, Ph.D., Founder and Chairman of the Sidero Board, states, “In partnership with SRS, we strive to provide a safe, effective, and cost-efficient treatment option for iron deficiency. The SRS health team understands the global impact of ID/IDA and are experts in launching transformational technologies, like BioFe, to fill significant unmet medical needs.”

About Sidero Bioscience

Sidero is advancing disruptive technologies utilizing the patented SiderosorbTM platform that employs nutritional Baker’s yeast, Saccharomyces cerevisiae, to provide therapeutic proteins/complexes to improve human health. BioFeTM is a nutritional yeast strain expressing very high levels of H-Ferritin, FTH1, a natural iron transport and storage protein. An illustrative example of the natural biology of the Ferritin/Iron complex is its presence in human breast milk, providing nursing infants the readily adsorbed iron required for growth and development without gastrointestinal upset. Sidero is currently preparing manuscripts detailing the preclinical and clinical development

U.S. signs agreement with AstraZeneca to develop, supply COVID-19 antibody treatment

(Reuters) – The U.S. government on Friday signed an agreement with AstraZeneca Plc <AZN.L> worth $486 million to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drugs that was used to treat President Donald Trump.

The U.S. health agency will provide the funding to AstraZeneca for two Phase 3 clinical trials under operation Warp Speed, which is aimed at speeding up treatments and vaccines for COVID-19.

One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months, in about 5,000 participants, while the second trial will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.

AstraZeneca said it plans to supply up to 100,000 doses starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.

In a video posted on Twitter on Wednesday, Trump credited Regeneron Pharmaceuticals Inc’s <REGN.O> therapeutic for his recovery. Trump received Regeneron’s treatment last week after he was diagnosed with COVID-19.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D’Silva)

Source Article

U.S. Signs Agreement With AstraZeneca to Develop, Supply COVID-19 Antibody Treatment | Top News

(Reuters) – The U.S. government on Friday signed an agreement with AstraZeneca Plc

worth $486 million to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drugs that was used to treat President Donald Trump.

The U.S. health agency will provide the funding to AstraZeneca for two Phase 3 clinical trials under operation Warp Speed, which is aimed at speeding up treatments and vaccines for COVID-19.

One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months, in about 5,000 participants, while the second trial will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.

AstraZeneca said it plans to supply up to 100,000 doses starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.

In a video posted on Twitter on Wednesday, Trump credited Regeneron Pharmaceuticals Inc’s

therapeutic for his recovery. Trump received Regeneron’s treatment last week after he was diagnosed with COVID-19.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D’Silva)

Copyright 2020 Thomson Reuters.

Source Article

Trump Required Walter Reed Staff To Sign Nondisclosure Agreement In 2019

KEY POINTS

  • During a trip to Walter Reed on Nov. 16, 2019, Trump allegedly required both physicians and nonmedical staff to sign an NDA
  • It’s still unknown whether the president required the Walter Reed staff to sign a nondisclosure in his most recent visit
  • Doctors tending to patients are prohibited by federal law from disclosing patients’ personal health information without consent

President Trump has required personnel at the Walter Reed National Military Medical Center to sign a nondisclosure agreement before treating him. 

During a trip to Walter Reed on Nov. 16, 2019, Trump required both physicians and nonmedical staff to sign an NDA. At least two doctors at Walter Reed refused to sign the NDAs and were not permitted to have any involvement in the president’s care, NBC News reported. 

It’s still unknown whether the president required the Walter Reed staff to sign a nondisclosure in his most recent visit. 

Doctors tending to patients are prohibited by federal law from disclosing patient’s personal health information without consent. The Health Insurance Portability and Accountability Act protects patients’ confidential health information, which raises the question of why Trump would ask staff members at Walter Reed to sign an NDA.

“Any physician caring for the President is bound by patient-physician confidentiality guaranteed under HIPAA, and I’m not going to comment on internal procedures beyond that,” White House Deputy Press Secretary Judd Deere said in a statement.

Transparency about Trump’s health has been a major concern since the president tested positive for COVID-19. Trump, his administration, and the physicians attending to him painted a murky picture of how the president is recovering. Dr. Sean Conley, the president’s physician, has refused to answer key questions, such as when Trump last tested negative for the virus and whether the illness has caused him to develop respiratory problems.

Conley continues to cite HIPAA when dodging questions on the president’s health. “We’ve done routine standard imaging. I’m just not at liberty to discuss,” Conley said on Monday. 

Conley’s written updates on Trump’s health have included the note “I release the following information with the permission of President Donald J. Trump.”

Source Article

Reyna Silver Signs Option Agreement for Medicine Springs Project in Nevada

Figure 1: Medicine Springs Location

Figure 1: Medicine Springs Location
Figure 1: Medicine Springs Location
Figure 1: Medicine Springs Location

Figure 2: Carbonate Replacement Deposit Model for Medicine Springs

Figure 2: Carbonate Replacement Deposit Model for Medicine Springs
Figure 2: Carbonate Replacement Deposit Model for Medicine Springs
Figure 2: Carbonate Replacement Deposit Model for Medicine Springs

Figure 3: NLR Exploration Results Medicine Springs

Figure 3: NLR Exploration Results Medicine Springs
Figure 3: NLR Exploration Results Medicine Springs
Figure 3: NLR Exploration Results Medicine Springs

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HONG KONG, Oct. 05, 2020 (GLOBE NEWSWIRE) — (“Reyna or RSLV”) is pleased to announce that it has entered into a Property Option Agreement with Northern Lights Resources Corp. (“NLR”) on the Medicine Springs silver-lead-zinc project (the “Medicine Springs Project”) located in Elko County, Nevada. The Medicine Springs Project comprises 149 unpatented Federal mineral claims covering 1,189 hectares located in the Ruby Mountains Valley just off the famous Carlin Trend.

The Agreement gives Reyna the ability to earn up to an 80% equity interest in the Project (initial 75% with option to purchase an additional 5%) (the “Option”) subject to expending a total of US$2,439,065 on the Project by December 31, 2023. Upon completion of the Option, Northern Lights and Reyna will enter a Joint Venture to continue exploration and development of the Medicine Springs Project, with Reyna acting as the project’s operator. No upfront payments in either cash or shares are due to either NLR or any other party. See below for the detailed terms.

“While Reyna Silver’s main focus will continue to be our flagship Guigui asset, for which we are awaiting permits to commence a 10,000 meter drill campaign this fall, we are delighted to add Medicine Springs to our portfolio of assets,” said Jorge Ramiro Monroy, President and CEO.   Medicine Springs is a Guigui-like CRD system with high-grade silver potential, which lies in Nevada’s CRD elephant country and we are eager to begin applying the same exploration model that led to Arizona Mining’s Taylor Manto and MAG Silver’s Cinco de Mayo discoveries. The Northern Lights team has done an excellent job developing the project to its current near-drill ready stage, which lets us hit the ground running.”

“Figure 1: Medicine Springs Location” is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6669eecf-7969-4d08-8495-284a455679fa

“Figure 2: Carbonate Replacement Deposit Model for Medicine Springs” is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b835479-ba68-435c-9e1d-ee4d62bb9525

The Medicine Springs Project

The world-famous Carlin Trend runs just east of the Medicine Springs area and prior to acquisition by NLR in 2017, the area was explored for Carlin-style gold potential from 1986-2008 by companies including, US Minerals Exploration, Golden Phoenix, Cominco America and Silver Resources. This exploration work included mapping, sampling, geophysics (CSAMT and IP) and shallow RC drilling. A total of 125 RC holes were drilled on the Project claims (5,380 m with average depth of 43 m, with the deepest hole being 180 m). Limited gold mineralization was found, but significant silver-rich mineralization was cut in several holes including: 33 m @ 90 g/t